Sung, H. et al. International Most cancers Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J. Clin. 71, 209–249 (2021).
Siegel, R., Desantis, C. & Jemal, A. Colorectal most cancers statistics, 2014. CA Most cancers J. Clin. 64, 104–117 (2014).
Ciardiello, F. et al. Scientific administration of metastatic colorectal most cancers within the period of precision drugs. CA Most cancers J. Clin. 72, 372–401 (2022).
O’Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon most cancers survival charges with the brand new American Joint Committee on Most cancers sixth version staging. J. Natl Most cancers Inst. 96, 1420–1425 (2004).
Yoshino, T. et al. Pan-Asian tailored ESMO consensus tips for the administration of sufferers with metastatic colorectal most cancers: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29, 44–70 (2018).
Biller, L. H. & Schrag, D. Prognosis and remedy of metastatic colorectal most cancers: a evaluation. J. Am. Med. Assoc. 325, 669–685 (2021).
Kwak, E. L., Clark, J. W. & Chabner, B. Focused brokers: the foundations of mixture. Clin. Most cancers Res. 13, 5232–5237 (2007).
van Engeland, M., Derks, S., Smits, Ok. M., Meijer, G. A. & Herman, J. G. Colorectal most cancers epigenetics: complicated simplicity. J. Clin. Oncol. 29, 1382–1391 (2011).
Shen, L. et al. Built-in genetic and epigenetic evaluation identifies three completely different subclasses of colon most cancers. Proc. Natl Acad. Sci. USA 104, 18654–18659 (2007).
Yagi, Ok. et al. Three DNA methylation epigenotypes in human colorectal most cancers. Clin. Most cancers Res. 16, 21–33 (2010).
Kambara, T. et al. BRAF mutation is related to DNA methylation in serrated polyps and cancers of the colorectum. Intestine 53, 1137–1144 (2004).
Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly related to BRAF mutation in colorectal most cancers. Nat. Genet. 38, 787–793 (2006).
Fleischer, T. et al. An built-in ‘omics strategy highlights the function of epigenetic occasions to clarify and predict response to neoadjuvant chemotherapy and bevacizumab. Preprint at bioRxiv https://doi.org/10.1101/2022.07.06.498803 (2022).
Gampenrieder, S. P. et al. DNA methylation signatures predicting bevacizumab efficacy in metastatic breast most cancers. Theranostics 8, 2278–2288 (2018).
Li, B. et al. Genome-wide DNA methylation signature predict scientific good thing about bevacizumab in non-small cell lung most cancers. BMC Most cancers 22, 828 (2022).
Oing, C. et al. 5-Azacitidine exerts extended pro-apoptotic results and overcomes cisplatin-resistance in non-seminomatous germ cell tumor cells. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20010021 (2018).
Meisenberg, C. et al. Epigenetic adjustments in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan. Nucleic Acids Res. 45, 1159–1176 (2017).
Wang, L. et al. Focusing on HDAC with a novel inhibitor successfully reverses paclitaxel resistance in non-small cell lung most cancers through a number of mechanisms. Cell Dying Dis. 7, e2063 (2016).
Wang, W. et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel goal to beat cisplatin resistance in human non-small cell lung most cancers. Mol Most cancers 19, 134 (2020).
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G. & Postel-Vinay, S. Combining epigenetic medicine with different therapies for strong tumours—previous classes and future promise. Nat. Rev. Clin. Oncol. 17, 91–107 (2020).
Rodger, E. J. et al. An epigenetic signature of superior colorectal most cancers metastasis. iScience 26, 106986 (2023).
Chen, H. N. et al. Genomic evolution and various fashions of systemic metastases in colorectal most cancers. Intestine 71, 322–332 (2022).
Dang, H. X. et al. The clonal evolution of metastatic colorectal most cancers. Sci. Adv. 6, eaay9691 (2020).
Mo, S. et al. Affected person-derived organoids from colorectal most cancers with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy. Adv. Sci. 9, e2204097 (2022).
Vlachogiannis, G. et al. Affected person-derived organoids mannequin remedy response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
Letai, A., Bhola, P. & Welm, A. L. Practical precision oncology: testing tumors with medicine to determine vulnerabilities and novel mixtures. Most cancers Cell 40, 26–35 (2022).
Rashid, M. et al. Optimizing drug mixtures in opposition to a number of myeloma utilizing a quadratic phenotypic optimization platform (QPOP). Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aan0941 (2018).
Ho, D., Wang, C. H. & Chow, E. Ok. Nanodiamonds: the intersection of nanotechnology, drug growth, and customized drugs. Sci. Adv. 1, e1500439 (2015).
Ho, D., Zarrinpar, A. & Chow, E. Ok. Diamonds, digital well being, and drug growth: optimizing combinatorial nanomedicine. ACS Nano https://doi.org/10.1021/acsnano.6b06174 (2016).
Al-Shyoukh, I. et al. Systematic quantitative characterization of mobile responses induced by a number of alerts. BMC Syst. Biol. 5, 88 (2011).
Goh, J. et al. An ex vivo platform to information drug mixture remedy in relapsed/refractory lymphoma. Sci. Transl. Med. 14, eabn7824 (2022).
Lim, J. J. et al. Rational drug mixture design in patient-derived avatars reveals efficient inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. J. Exp. Clin. Most cancers Res. 41, 249 (2022).
Thng, D. Ok. H. et al. Splice-switch oligonucleotide-based combinatorial platform prioritizes artificial deadly targets CHK1 and BRD4 in opposition to MYC-driven hepatocellular carcinoma. Bioeng. Transl. Med. 8, e10363 (2023).
van de Wetering, M. et al. Potential derivation of a dwelling organoid biobank of colorectal most cancers sufferers. Cell 161, 933–945 (2015).
Ooft, S. N. et al. Affected person-derived organoids can predict response to chemotherapy in metastatic colorectal most cancers sufferers. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aay2574 (2019).
Kummar, S., Fogarasi, M., Canova, A., Mota, A. & Ciesielski, T. Cytokeratin 7 and 20 staining for the prognosis of lung and colorectal adenocarcinoma. Br. J. Most cancers 86, 1884–1887 (2002).
Kim, J. H., Rhee, Y. Y., Bae, J. M., Cho, N. Y. & Kang, G. H. Lack of CDX2/CK20 expression is related to poorly differentiated carcinoma, the CpG island methylator phenotype, and opposed prognosis in microsatellite-unstable colorectal most cancers. Am. J. Surg. Pathol. 37, 1532–1541 (2013).
McGregor, D. Ok., Wu, T. T., Rashid, A., Luthra, R. & Hamilton, S. R. Decreased expression of cytokeratin 20 in colorectal carcinomas with excessive ranges of microsatellite instability. Am. J. Surg. Pathol. 28, 712–718 (2004).
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal most cancers. Lancet 394, 1467–1480 (2019).
Dalerba, P. et al. Phenotypic characterization of human colorectal most cancers stem cells. Proc. Natl Acad. Sci. USA 104, 10158–10163 (2007).
Kawai, T. et al. SOX9 is a novel most cancers stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci. Rep. 6, 30489 (2016).
Zhou, T. et al. SOX9-activated FARSA-AS1 predetermines cell development, stemness, and metastasis in colorectal most cancers by way of upregulating FARSA and SOX9. Cell Dying Dis. 11, 1071 (2020).
Sanchez-Vega, F. et al. Oncogenic signaling pathways within the most cancers genome atlas. Cell 173, 321–337 e310 (2018).
Fearon, E. R. & Vogelstein, B. A genetic mannequin for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Most cancers Genome Atlas, N. Complete molecular characterization of human colon and rectal most cancers. Nature 487, 330–337 (2012).
Bass, A. J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964–968 (2011).
Lawrence, M. S. et al. Discovery and saturation evaluation of most cancers genes throughout 21 tumour sorts. Nature 505, 495–501 (2014).
Hendrickx, W., Roelands, J., Kuppen, P., Marincola, F. & Bedognetti, D. The Sidra LUMC superior colon most cancers NGS cohort. Ann. Oncol. 30, ix32–ix33 (2019).
Takebayashi, Ok. et al. Variations in chemosensitivity between major and metastatic tumors in colorectal most cancers. PLoS ONE 8, e73215 (2013).
Xu, H., Jaynes, J. & Ding, X. Combining two-level and three-level orthogonal arrays for issue screening and response floor exploration. Stat. Sin. 24, 269–289 (2014).
Cobain, E. F. et al. Evaluation of scientific good thing about integrative genomic profiling in superior strong tumors. JAMA Oncol. 7, 525–533 (2021).
Massard, C. et al. Excessive-throughput genomics and scientific final result in hard-to-treat superior cancers: outcomes of the MOSCATO 01 trial. Most cancers Discov. 7, 586–595 (2017).
Hoes, L. R. et al. Sufferers with uncommon cancers within the drug rediscovery protocol (DRUP) profit from genomics-guided remedy. Clin. Most cancers Res. 28, 1402–1411 (2022).
Broutier, L. et al. Human major liver cancer-derived organoid cultures for illness modeling and drug screening. Nat. Med. 23, 1424–1435 (2017).
Driehuis, E. et al. Pancreatic most cancers organoids recapitulate illness and permit customized drug screening. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1911273116 (2019).
Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid fashions of bladder most cancers. Cell 173, 515–528.e517 (2018).
Yan, H. H. N. et al. A complete human gastric most cancers organoid biobank captures tumor subtype heterogeneity and allows therapeutic screening. Cell Stem Cell 23, 882–897.e811 (2018).
Sachs, N. et al. A dwelling biobank of breast most cancers organoids captures illness heterogeneity. Cell 172, 373–386.e310 (2018).
Narasimhan, V. et al. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct customized remedy. Clin. Most cancers Res. 26, 3662–3670 (2020).
Martini, G. et al. Institution of patient-derived tumor organoids to functionally inform remedy choices in metastatic colorectal most cancers. ESMO Open 8, 101198 (2023).
Hafner, M., Niepel, M., Chung, M. & Sorger, P. Ok. Development price inhibition metrics right for confounders in measuring sensitivity to most cancers medicine. Nat. Strategies 13, 521–527 (2016).
Palmer, A. C., Izar, B., Hwangbo, H. & Sorger, P. Ok. Predictable scientific advantages with out proof of synergy in trials of mixture therapies with immune-checkpoint inhibitors. Clin. Most cancers Res. 28, 368–377 (2022).
Palmer, A. C. & Sorger, P. Ok. Mixture most cancers remedy can confer profit through patient-to-patient variability with out drug additivity or synergy. Cell 171, 1678–1691.e1613 (2017).
Cheng, Y. et al. Focusing on epigenetic regulators for most cancers remedy: mechanisms and advances in scientific trials. Sign Transduct Goal Ther. 4, 62 (2019).
Huang, T. H. et al. The identification and validation of Trichosstatin A as a possible inhibitor of colon tumorigenesis and colon most cancers stem-like cells. Am. J. Most cancers Res. 7, 1227–1237 (2017).
Okada, Ok. et al. Mixture of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates main histocompatibility complicated class II and p21 genes and prompts caspase-3/7 in human colon most cancers HCT-116 cells. Oncol. Rep. 36, 1875–1885 (2016).
Tumber, A. et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon most cancers cell development in vitro and in vivo. Most cancers Chemother. Pharmacol. 60, 275–283 (2007).
Kim, J. C. et al. In vitro analysis of histone deacetylase inhibitors as mixture brokers for colorectal most cancers. Anticancer Res. 29, 3027–3034 (2009).
Fakih, M. G., Groman, A., McMahon, J., Wilding, G. & Muindi, J. R. A randomized section II research of two doses of vorinostat together with 5-FU/LV in sufferers with refractory colorectal most cancers. Most cancers Chemother. Pharmacol. 69, 743–751 (2012).
Fakih, M. G. et al. A section I, pharmacokinetic, and pharmacodynamic research of two schedules of vorinostat together with 5-fluorouracil and leucovorin in sufferers with refractory strong tumors. Clin Most cancers Res. 16, 3786–3794 (2010).
Wang, Q. et al. Oncogenic Ok-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. Oncotarget 7, 10064–10072 (2016).
Moufarrij, S. et al. Combining DNMT and HDAC6 inhibitors will increase anti-tumor immune signaling and reduces tumor burden in ovarian most cancers. Sci. Rep. 10, 3470 (2020).
Pathania, R. et al. Mixed inhibition of DNMT and HDAC blocks the tumorigenicity of most cancers stem-like cells and attenuates mammary tumor development. Most cancers Res. 76, 3224–3235 (2016).
Connolly, R. M. et al. Summary 4666: A section 2 research investigating the security, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in sufferers with triple-negative superior breast most cancers. Most cancers Res. 73, 4666–4666 (2013).
Weeber, F. et al. Preserved genetic range in organoids cultured from biopsies of human colorectal most cancers metastases. Proc. Natl Acad. Sci. USA 112, 13308–13311 (2015).
Carter, E. P., Roozitalab, R., Gibson, S. V. & Grose, R. P. Tumour microenvironment 3D-modelling: simplicity to complexity and again once more. Traits Most cancers 7, 1033–1046 (2021).
Giantonio, B. J. et al. Bevacizumab together with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for beforehand handled metastatic colorectal most cancers: outcomes from the Japanese Cooperative Oncology Group Research E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
Andre, T. et al. Pembrolizumab in microsatellite-instability-high superior colorectal most cancers. N. Engl. J. Med. 383, 2207–2218 (2020).
Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal most cancers (KEYNOTE-177): closing evaluation of a randomised, open-label, section 3 research. Lancet Oncol. 23, 659–670 (2022).
Overman, M. J. et al. Nivolumab in sufferers with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal most cancers (CheckMate 142): an open-label, multicentre, section 2 research. Lancet Oncol. 18, 1182–1191 (2017).
Yuki, Ok., Cheng, N., Nakano, M. & Kuo, C. J. Organoid fashions of tumor immunology. Traits Immunol. 41, 652–664 (2020).
Driehuis, E., Kretzschmar, Ok. & Clevers, H. Institution of patient-derived most cancers organoids for drug-screening functions. Nat. Protoc. 15, 3380–3409 (2020).
Fong, E. L. S. et al. Technology of matched patient-derived xenograft in vitro-in vivo fashions utilizing 3D macroporous hydrogels for the research of liver most cancers. Biomaterials 159, 229–240 (2018).
Sato, T. et al. Lengthy-term enlargement of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
Li, H. & Durbin, R. Quick and correct quick learn alignment with Burrows-Wheeler remodel. Bioinformatics 25, 1754–1760 (2009).
DePristo, M. A. et al. A framework for variation discovery and genotyping utilizing next-generation DNA sequencing information. Nat. Genet. 43, 491–498 (2011).
Cibulskis, Ok. et al. Delicate detection of somatic level mutations in impure and heterogeneous most cancers samples. Nat. Biotechnol. 31, 213–219 (2013).
Saunders, C. T. et al. Strelka: correct somatic small-variant calling from sequenced tumor-normal pattern pairs. Bioinformatics 28, 1811–1817 (2012).
Wang, Ok., Li, M. & Hakonarson, H. ANNOVAR: practical annotation of genetic variants from high-throughput sequencing information. Nucleic Acids Res. 38, e164 (2010).
Karczewski, Ok. J. et al. The mutational constraint spectrum quantified from variation in 141,456 people. Nature 581, 434–443 (2020).
Liu, M. et al. MesKit: a software equipment for dissecting most cancers evolution of multi-region tumor biopsies by way of somatic alterations. Gigascience https://doi.org/10.1093/gigascience/giab036 (2021).
Zheng, S. et al. SynergyFinder Plus: towards higher interpretation and annotation of drug mixture screening datasets. Genomics Proteomics Bioinform. 20, 587–596 (2022).
